FDA extends review of Ascendis Pharma's hormone disorder therapy

Ascendis Pharma A/S

14/05/2024 19:38

May 14 (Reuters) - 
    The U.S. Food & Drug Administration has extended its review
of Ascendis Pharma's  A71.F  therapy to treat adult patients
with a hormone disorder, the company said on Tuesday.
    The FDA is now set to make its decision known by Aug. 14,
compared to its previous action date set for May 14.
     

 (Reporting by Sriparna Roy and Sneha S K in Bengaluru; Editing
by Krishna Chandra Eluri and Shailesh Kuber)
 ((Sriparna.Roy@thomsonreuters.com;))